Inovio Pharmaceuticals (NASDAQ:INO) Stock Gets Downgrade from Zacks Research

Inovio Pharmaceuticals (NASDAQ:INO) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

Several other equities analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Piper Sandler reiterated an “overweight” rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and boosted their price target for the stock from $1.80 to $3.00 in a research note on Thursday, August 13th. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Thursday, August 13th. Finally, Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $3.17.

Inovio Pharmaceuticals Trading Down 9.7%

Inovio Pharmaceuticals stock opened at $1.00 on Monday. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.72. The firm’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.17.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. On average, equities analysts forecast that Inovio Pharmaceuticals will post -0.72 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Eversept Partners LP bought a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at approximately $1,802,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Inovio Pharmaceuticals by 1,929.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 46,536 shares in the last quarter. Green Alpha Advisors LLC grew its holdings in shares of Inovio Pharmaceuticals by 68.8% in the third quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 46,802 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Inovio Pharmaceuticals in the second quarter worth $37,000. Finally, Squarepoint Ops LLC increased its position in Inovio Pharmaceuticals by 46.5% in the second quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,554 shares during the last quarter. Institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (NASDAQ: INO) is a biotechnology company focused on developing DNA medicines, including immunotherapies and vaccines designed to stimulate targeted immune responses. Its technology platform uses synthetic DNA constructs delivered into cells, with the company’s CELLECTRA device platform developed to enhance cellular uptake.

Inovio’s pipeline has included candidates for infectious diseases, cancers and other conditions involving the immune system. Its lead programs have included INO-3107, an investigational DNA immunotherapy being developed for recurrent respiratory papillomatosis, and VGX-3100, an earlier candidate studied for human papillomavirus-related disease.